Resmetirom for metabolic dysfunction-associated steatohepatitis:targeting hepatic and cardiovascular disease  

作　　者：Isabella Lurje Frank Tacke 

机构地区：[1]Department of Hepatology and Gastroenterology,Campus CharitéMitte and Campus Virchow-Klinikum,Charité-Universitätsmedizin Berlin,Berlin,Germany [2]Department of General,Visceral and Transplantation Surgery,Heidelberg University Hospital,Heidelberg,Germany

出　　处：《Hepatobiliary Surgery and Nutrition》2024年第6期1034-1037,共4页肝胆外科与营养(英文)

摘　　要：Metabolic dysfunction-associated steatotic liver disease(MASLD)is defined as hepatic steatosis with at least one concomitant cardiovascular risk factor,and has emerged as the most frequent liver disease worldwide(1).It conveys risks of liver disease progression to metabolic dysfunction-associated steatohepatitis(MASH)and of cardiovascular events(2).

关 键 词：Metabolic dysfunction-associated steatotic liver disease(MASLD) metabolic dysfunctionassociated steatohepatitis(MASH) nonalcoholic fatty liver disease(NAFLD) nonalcoholic steatohepatitis(NASH) thyroid receptors 

分 类 号：R57[医药卫生—消化系统]